Amedisys, Inc. (NASDAQ:AMED) Short Interest Update

Posted by Defense World Staff on Mar 16th, 2023

Amedisys, Inc. (NASDAQ:AMED – Get Rating) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,090,000 shares, a growth of 7.2% from the February 13th total of 1,950,000 shares. Based on an average daily volume of 427,600 shares, the short-interest ratio is currently 4.9 days. Currently, 6.6% of the company’s shares are short sold.

Analyst Ratings Changes

A number of analysts have weighed in on AMED shares. Royal Bank of Canada lowered their target price on Amedisys from $114.00 to $111.00 and set an “outperform” rating for the company in a report on Tuesday, February 21st. Oppenheimer decreased their price objective on Amedisys from $145.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, January 19th. Credit Suisse Group reiterated an “outperform” rating and set a $115.00 price objective on shares of Amedisys in a report on Monday, February 27th. Benchmark reiterated a “buy” rating and set a $115.00 price objective on shares of Amedisys in a report on Tuesday. Finally, Stephens reiterated an “equal weight” rating and set a $103.00 price objective on shares of Amedisys in a report on Tuesday. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $119.53.

Amedisys Price Performance

Shares of AMED opened at $77.45 on Thursday. The business’s 50-day moving average is $90.18 and its two-hundred day moving average is $94.24. The company has a market capitalization of $2.52 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 1.04. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.09 and a current ratio of 1.09. Amedisys has a fifty-two week low of $76.93 and a fifty-two week high of $179.91.

Amedisys (NASDAQ:AMED – Get Rating) last announced its quarterly earnings results on Thursday, February 16th. The health services provider reported $1.16 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.13. The company had revenue of $562.10 million for the quarter, compared to the consensus estimate of $560.46 million. Amedisys had a return on equity of 15.44% and a net margin of 5.34%. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the firm earned $1.18 EPS. Research analysts predict that Amedisys will post 4.26 earnings per share for the current year.

Insider Activity at Amedisys

In related news, insider Michael Paul North sold 5,908 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $86.43, for a total value of $510,628.44. Following the completion of the sale, the insider now owns 4,164 shares in the company, valued at $359,894.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amedisys

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMED. BlackRock Inc. grew its position in shares of Amedisys by 1.5% during the 3rd quarter. BlackRock Inc. now owns 3,960,416 shares of the health services provider’s stock valued at $383,327,000 after acquiring an additional 57,035 shares during the period. Vanguard Group Inc. grew its position in shares of Amedisys by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,042,027 shares of the health services provider’s stock valued at $294,438,000 after acquiring an additional 10,457 shares during the period. Wellington Management Group LLP grew its position in shares of Amedisys by 3.5% during the 1st quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider’s stock valued at $323,092,000 after acquiring an additional 62,863 shares during the period. JPMorgan Chase & Co. grew its position in shares of Amedisys by 3.4% during the 4th quarter. JPMorgan Chase & Co. now owns 1,759,870 shares of the health services provider’s stock valued at $147,020,000 after acquiring an additional 58,365 shares during the period. Finally, Riverbridge Partners LLC grew its position in shares of Amedisys by 8.2% during the 3rd quarter. Riverbridge Partners LLC now owns 1,628,273 shares of the health services provider’s stock valued at $157,601,000 after acquiring an additional 123,286 shares during the period. 96.17% of the stock is owned by institutional investors and hedge funds.

About Amedisys

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.